209 related articles for article (PubMed ID: 35688062)
1. Effect of KRAS codon 12 or 13 mutations on survival with trifluridine/tipiracil in pretreated metastatic colorectal cancer: a meta-analysis.
Yoshino T; Van Cutsem E; Li J; Shen L; Kim TW; Sriuranpong V; Xuereb L; Aubel P; Fougeray R; Cattan V; Amellal N; Ohtsu A; Mayer RJ
ESMO Open; 2022 Jun; 7(3):100511. PubMed ID: 35688062
[TBL] [Abstract][Full Text] [Related]
2. Impact of KRAS
Tabernero J; Taieb J; Fakih M; Prager GW; Van Cutsem E; Ciardiello F; Mayer RJ; Amellal N; Skanji D; Calleja E; Yoshino T
ESMO Open; 2024 Mar; 9(3):102945. PubMed ID: 38471240
[TBL] [Abstract][Full Text] [Related]
3. Codon-specific KRAS mutations predict survival benefit of trifluridine/tipiracil in metastatic colorectal cancer.
van de Haar J; Ma X; Ooft SN; van der Helm PW; Hoes LR; Mainardi S; Pinato DJ; Sun K; Salvatore L; Tortora G; Zurlo IV; Leo S; Giampieri R; Berardi R; Gelsomino F; Merz V; Mazzuca F; Antonuzzo L; Rosati G; Stavraka C; Ross P; Rodriquenz MG; Pavarana M; Messina C; Iveson T; Zoratto F; Thomas A; Fenocchio E; Ratti M; Depetris I; Cergnul M; Morelli C; Libertini M; Parisi A; De Tursi M; Zanaletti N; Garrone O; Graham J; Longarini R; Gobba SM; Petrillo A; Tamburini E; La Verde N; Petrelli F; Ricci V; Wessels LFA; Ghidini M; Cortellini A; Voest EE; Valeri N
Nat Med; 2023 Mar; 29(3):605-614. PubMed ID: 36864254
[TBL] [Abstract][Full Text] [Related]
4. Bevacizumab mitigates codon-specific effects of trifluridine/tipiracil on efficacy outcome parameters in metastatic colorectal cancer.
Doleschal B; Taghizadeh H; Lentner T; Riedl JM; Granitzer J; Morariu D; Decker J; Aichberger KJ; Webersinke G; Kirchweger P; Petzer A; Rumpold H
ESMO Open; 2023 Dec; 8(6):102064. PubMed ID: 37977001
[TBL] [Abstract][Full Text] [Related]
5. A systematic review of observational studies of trifluridine/tipiracil (TAS-102) for metastatic colorectal cancer.
Andersen SE; Andersen IB; Jensen BV; Pfeiffer P; Ota T; Larsen JS
Acta Oncol; 2019 Aug; 58(8):1149-1157. PubMed ID: 31002008
[No Abstract] [Full Text] [Related]
6. Pooled safety analysis from phase III studies of trifluridine/tipiracil in patients with metastatic gastric or gastroesophageal junction cancer and metastatic colorectal cancer.
Van Cutsem E; Hochster H; Shitara K; Mayer R; Ohtsu A; Falcone A; Yoshino T; Doi T; Ilson DH; Arkenau HT; George B; Benhadji KA; Makris L; Tabernero J
ESMO Open; 2022 Dec; 7(6):100633. PubMed ID: 36455504
[TBL] [Abstract][Full Text] [Related]
7. Quality of Life and Survival of Metastatic Colorectal Cancer Patients Treated With Trifluridine-Tipiracil (QUALITAS).
Hamers PAH; Vink GR; Elferink MAG; Stellato RK; Dijksterhuis WPM; Punt CJA; Koopman M; May AM;
Clin Colorectal Cancer; 2022 Jun; 21(2):154-166. PubMed ID: 35474007
[TBL] [Abstract][Full Text] [Related]
8. Trifluridine/Tipiracil Plus Bevacizumab for Vulnerable Patients With Pretreated Metastatic Colorectal Cancer: A Retrospective Study (WJOG14520G).
Kito Y; Kawakami H; Mitani S; Nishina S; Matsumoto T; Tsuzuki T; Shinohara Y; Shimokawa H; Kumanishi R; Ohta T; Katsuya H; Kawakami T; Nishina T; Hasegawa H; Akiyoshi K; Chiba Y; Yamazaki K; Hironaka S; Muro K
Oncologist; 2024 Mar; 29(3):e330-e336. PubMed ID: 37950903
[TBL] [Abstract][Full Text] [Related]
9. Sequential Treatment With Trifluridine/Tipiracil and Regorafenib in Refractory Metastatic Colorectal Cancer Patients: An AGEO Prospective "Real-World Study".
Coutzac C; Trouilloud I; Artru P; Henriques J; Masson T; Doat S; Bouché O; Coriat R; Saint A; Moulin V; Vernerey D; Gallois C; De La Fouchardière C; Tougeron D; Taieb J
Clin Colorectal Cancer; 2022 Jun; 21(2):132-140. PubMed ID: 35337742
[TBL] [Abstract][Full Text] [Related]
10. Neutropenia and survival outcomes in metastatic colorectal cancer patients treated with trifluridine/tipiracil in the RECOURSE and J003 trials.
Yoshino T; Cleary JM; Van Cutsem E; Mayer RJ; Ohtsu A; Shinozaki E; Falcone A; Yamazaki K; Nishina T; Garcia-Carbonero R; Komatsu Y; Baba H; Argilés G; Tsuji A; Sobrero A; Yamaguchi K; Peeters M; Muro K; Zaniboni A; Sugimoto N; Shimada Y; Tsuji Y; Hochster HS; Moriwaki T; Tran B; Esaki T; Hamada C; Tanase T; Benedetti F; Makris L; Yamashita F; Lenz HJ
Ann Oncol; 2020 Jan; 31(1):88-95. PubMed ID: 31912801
[TBL] [Abstract][Full Text] [Related]
11. Real-World Adherence in Patients with Metastatic Colorectal Cancer Treated with Trifluridine plus Tipiracil or Regorafenib.
Patel AK; Barghout V; Yenikomshian MA; Germain G; Jacques P; Laliberté F; Duh MS
Oncologist; 2020 Jan; 25(1):e75-e84. PubMed ID: 31591140
[TBL] [Abstract][Full Text] [Related]
12. Effectiveness, safety and quality of life of trifluridine/tipiracil in pretreated patients with metastatic colorectal cancer: Real-world data from the noninterventional TACTIC study in Germany.
Kröning H; Göhler T; Decker T; Grundeis M; Kojouharoff G; Lipke J; Semsek D; Moorahrend E; Sauer A; Bruch HR; Liersch R; Nusch A; Vehling-Kaiser U; Welslau M; Grunewald R; Harich HD; Stephany M; Uhlig J; de Buhr R; Frank M; Hogrefe C; Marschner N; Potthoff K; Hartmann F; Reisländer T; Schwaner I
Int J Cancer; 2023 Sep; 153(6):1227-1240. PubMed ID: 37260368
[TBL] [Abstract][Full Text] [Related]
13. The subgroups of the phase III RECOURSE trial of trifluridine/tipiracil (TAS-102) versus placebo with best supportive care in patients with metastatic colorectal cancer.
Van Cutsem E; Mayer RJ; Laurent S; Winkler R; Grávalos C; Benavides M; Longo-Munoz F; Portales F; Ciardiello F; Siena S; Yamaguchi K; Muro K; Denda T; Tsuji Y; Makris L; Loehrer P; Lenz HJ; Ohtsu A;
Eur J Cancer; 2018 Feb; 90():63-72. PubMed ID: 29274618
[TBL] [Abstract][Full Text] [Related]
14. Exploratory Biomarker Analysis Using Plasma Angiogenesis-Related Factors and Cell-Free DNA in the TRUSTY Study: A Randomized, Phase II/III Study of Trifluridine/Tipiracil Plus Bevacizumab as Second-Line Treatment for Metastatic Colorectal Cancer.
Sunakawa Y; Kuboki Y; Watanabe J; Terazawa T; Kawakami H; Yokota M; Nakamura M; Kotaka M; Sugimoto N; Ojima H; Oki E; Kajiwara T; Yamamoto Y; Tsuji Y; Denda T; Tamura T; Ishihara S; Taniguchi H; Nakajima TE; Morita S; Shirao K; Takenaka N; Ozawa D; Yoshino T
Target Oncol; 2024 Jan; 19(1):59-69. PubMed ID: 38194163
[TBL] [Abstract][Full Text] [Related]
15. Phase II study of trifluridine/tipiracil plus bevacizumab by RAS mutation status in patients with metastatic colorectal cancer refractory to standard therapies: JFMC51-1702-C7.
Takahashi T; Yamazaki K; Oki E; Shiozawa M; Mitsugi K; Makiyama A; Nakamura M; Ojima H; Kagawa Y; Matsuhashi N; Okuda H; Asayama M; Yuasa Y; Shimada Y; Manaka D; Watanabe J; Oba K; Yoshino T; Yoshida K; Maehara Y
ESMO Open; 2021 Apr; 6(2):100093. PubMed ID: 33744811
[TBL] [Abstract][Full Text] [Related]
16. Comparative Efficacy and Safety of Standard and Biweekly Trifluridine/Tipiracil Regimen in Patients With Colorectal Cancer.
Hara S; Sakai D; Ikemura K; Shintani T; Yamamoto T; Satoh T; Okuda M
Anticancer Res; 2024 Mar; 44(3):1219-1226. PubMed ID: 38423630
[TBL] [Abstract][Full Text] [Related]
17. Trifluridine/tipiracil versus placebo for third or later lines of treatment in metastatic gastric cancer: an exploratory subgroup analysis from the TAGS study.
Tabernero J; Shitara K; Zaanan A; Doi T; Lorenzen S; Van Cutsem E; Fornaro L; Catenacci DVT; Fougeray R; Moreno SR; Azcue P; Arkenau HT; Alsina M; Ilson DH
ESMO Open; 2021 Aug; 6(4):100200. PubMed ID: 34175675
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of trifluridine/tipiracil in older and younger patients with metastatic gastric or gastroesophageal junction cancer: subgroup analysis of a randomized phase 3 study (TAGS).
Shitara K; Doi T; Hosaka H; Thuss-Patience P; Santoro A; Longo F; Ozyilkan O; Cicin I; Park D; Zaanan A; Pericay C; Özgüroğlu M; Alsina M; Makris L; Benhadji KA; Ilson DH
Gastric Cancer; 2022 May; 25(3):586-597. PubMed ID: 34997449
[TBL] [Abstract][Full Text] [Related]
19. Real-world evidence of trifluridine/tipiracil plus bevacizumab in metastatic colorectal cancer using an administrative claims database in Japan.
Kagawa Y; Shinozaki E; Okude R; Tone T; Kunitomi Y; Nakashima M
ESMO Open; 2023 Aug; 8(4):101614. PubMed ID: 37562196
[TBL] [Abstract][Full Text] [Related]
20. Efficacy of Chemotherapy Rechallenge Versus Regorafenib or Trifluridine/Tipiracil in Third-Line Setting of Metastatic Colorectal Cancer: A Multicenter Retrospective Comparative Study.
Bazarbashi S; Alkhatib R; Aseafan M; Tuleimat Y; Abdel-Aziz N; Mahrous M; Elsamany S; Elhassan T; Alghamdi M
JCO Glob Oncol; 2024 Mar; 10():e2300461. PubMed ID: 38484194
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
